| Literature DB >> 34897240 |
Blake Linthwaite1, Nadine Kronfli1,2, Ivan Marbaniang3, Luciana Ruppenthal2, David Lessard1, Kim Engler1, Bertrand Lebouché1,2,4, Joseph Cox1,2,3.
Abstract
BACKGROUND: Negative health outcomes associated with being out of HIV care (OOC) warrant reengagement strategies. We aimed to assess effectiveness of Lost & Found, a clinic-based intervention to identify and reengage OOC patients.Entities:
Mesh:
Year: 2022 PMID: 34897240 PMCID: PMC8876436 DOI: 10.1097/QAD.0000000000003147
Source DB: PubMed Journal: AIDS ISSN: 0269-9370 Impact factor: 4.177
Fig. 1Out of care risk prediction tool.
Fig. 2Summary of Lost & Found outcomes: (a) among all patients in the clinical electronic medical record, (b) among out of care patients only, and (c) among out of care patients contacted but not yet reengaged.
Baseline characteristics of contacted out of care patients, stratified by reengagement.
| OOC, contacted | Contacted and reengaged | Contacted, not yet reengaged | |
|
| 359 | 250 | 109 |
| Sex [ | |||
| Female | 124 (34.5%) | 87 (34.8%) | 37 (33.9%) |
| Male | 235 (65.5%) | 163 (65.2%) | 72 (66.1%) |
| Age, median [IQR] | 51 [42–57] | 52 [42–58] | 50 [40–56] |
| Born in Canada [ | 155 (43.2%) | 108 (43.2%) | 47 (43.1%) |
| Years since HIV diagnosis, median [IQR] | 16 [11–23] | 17 [11–23] | 16 [11–22] |
| Risk categorya | |||
| High | 40 (11.1%) | 26 (10.4%) | 14 (12.8%) |
| CD4+ cell count <100 | 14 (3.9%) | 12 (4.8%) | 2 (1.8%) |
| CD4+ cell count 100–200 + VL ≥40 | 12 (3.3%) | 8 (3.2%) | 4 (3.7%) |
| New patient | 3 (0.8%) | 1 (0.4%) | 2 (1.8%) |
| Other/clinical judgement | 11 (3.0%) | 5 (2.0%) | 6 (5.5%) |
| Intermediate | 262 (73.0%) | 197 (78.8%) | 65 (59.6%) |
| CD4+ cell count 100–300 + VL < 40 | 32 (8.9%) | 27 (10.8%) | 5 (4.6%) |
| CD4+ cell count ≥200 + VL ≥40 | 50 (13.9%) | 29 (11.6%) | 21 (19.3%) |
| Non-ART polypharmacy (>5 non-antiretrovirals) | 107 (29.8%) | 83 (33.2%) | 24 (22.0%) |
| History of chronic HCV infectionb | 30 (8.4%) | 21 (8.4%) | 9 (8.3%) |
| Youth (<25 years old) | 13 (3.6%) | 11 (4.4%) | 2 (1.8%) |
| CD4+ cell count nadir <200 | 155 (43.2%) | 126 (50.4%) | 29 (26.6%) |
| Other/clinical judgement | 3 (0.9%) | 2 (0.8%) | 1 (0.9%) |
| Low | 57 (15.9%) | 27 (10.8%) | 30 (27.5%) |
| CD4+ cell count ≥300 + VL <40 | 53 (14.8%) | 25 (10.0%) | 28 (25.7%) |
| Other/clinical judgement | 4 (1.1%) | 2 (0.8%) | 2 (1.8%) |
| History of chronic HCV infectionb [ | 42 (11.7%) | 30 (12.0%) | 12 (11.0%) |
| CD4+ cell count nadirc (cells/μl), median [IQR] | 184 [78–335] | 164 [71–310] | 274 [134–474] |
Among contacted OOC patients at the CVIS-MUHC clinic from 15 April 2018 to 15 April 2019 (n = 359). ART, antiretroviral therapy; IQR, interquartile range; OOC, out of HIV care; VL, viral load.
Risk category criteria, by risk category: High: CD4+ cell count less than 100 cells/μl (irrespective of viral load) or CD4+ cell count 100–200 cells/μl with viral load greater than 40 copies/ml or New patient. Intermediate: CD4+ cell count 100–300 cells/μl with viral load less than 40 copies/ml or CD4+ cell count greater than 200 cells/μl + viral load greater than 40 copies/ml or non-ART polypharmacy (>5 non-antiretrovirals) or Hx of chronic HCV infection (HCV RNA+) or Youth (<25 years old) or CD4+ cell count nadir less than 200 cells/μl. Low: CD4+ cell count greater than 300 cells/μl + viral load less than 40 copies/ml. Risk categories are mutually exclusive. For the criteria within each risk category, only the CD4+ cell count and viral load criteria are mutually exclusive from each other; otherwise multiple criteria can apply to the same patient. ‘Other’ refers to a nurse defined reason for classification into the given risk category.
Ever HCV RNA+.
Lowest CD4+ cell count on record before reengagement.
Characteristics of patients contacted and reengaged.
| Risk category | Overall | High riska | Intermediate riska | Low riska | |
| 250 | 26 (10%) | 197 (79%) | 27 (11%) | ||
| CD4+ cell count | |||||
| CD4+ cell count; median [IQR] | Reengagement | 528 [351–744] | 151 [72–314] | 544 [379–770] | 704 [574–850] |
| Previous visit | 538 [350–731] | 139 [84–257] | 551 [378–730] | 751 [612–873] | |
| CD4%, median [IQR] | Reengagement | 30 [21–38] | 12 [5–17] | 31 [23–38] | 35 [30–41] |
| Previous visit | 28 [21–37] | 12 [7–14] | 29 [23–37] | 34 [30–38] | |
| CD4+/CD8+ ratio, median [IQR] | Reengagement | 0.70 [0.40–1.10] | 0.20 [0.10–0.30] | 0.70 [0.50–1.10] | 1.10 [0.75–1.35] |
| Previous visit | 0.70 [0.40–1.08] | 0.20 [0.10–0.30] | 0.70 [0.50–1.07] | 1.00 [0.75–1.20] | |
| VLb | |||||
| VL, median [IQR] | Reengagement | <40 [<40 to <40] | 116 [<40 to 37 646] | <40 [<40 to <40] | <40 [<40 to <40] |
| Previous visit | <40 [<40 to <40] | 203 [<40 to 21 376] | <40 [<40 to <40] | <40 [<40 to <40] | |
| Undetectable VL [ | Reengagement | 197 (79%) | 11 (42%) | 162 (82%) | 24 (89%) |
| Previous visit | 197 (79%) | 7 (27%) | 163 (83%) | 27 (100%) | |
| Viremia [ | Reengagement | 38 (15.2%) | 12 (46.2%) | 24 (12.2%) | 2 (7.4%) |
| Previous visit | 30 (12.0%) | 13 (50.0%) | 17 (8.6%) | 0 (0.0%) | |
| Days from… (median [IQR]) | …Previous visit to reengagement | 315 [246–448] | 229 [168–428] | 304 [247–422] | 444 [427–514] |
| …First contact attempt to reengagement | 72 [34–136] | 86 [37–107] | 78 [34–145] | 57 [34–78] | |
| Any missed visits reengagement visits [ | 92 (37%) | 14 (54%) | 73 (37%) | 5 (19%) | |
| Number of contact attempts, median [IQR] | 2.0 [1.0–4.0] | 4.0 [1.5–5.0] | 2.0 [1.0–4.0] | 2.0 [1.0–2.5] | |
Among OOC patients contacted and reengaged into care at the CVIS-MUHC clinic from 15 April 2018 to 15 April 2019 (n = 250). IQR, interquartile range; OOC, out of HIV care; VL, viral load.
Risk category criteria: High: CD4+ cell count less than 100 cells/μl (irrespective of viral load) or CD4+ cell count 100–200 cells/μl with viral load greater than 40 copies/ml or new patient. Intermediate: CD4+ cell count 100–300 cells/μl + viral load less than 40 copies/ml or CD4+ cell count greater than 200 cells/μl with viral load greater than 40 copies/ml or non-ART polypharmacy (>5 non-antiretrovirals) or Hx of chronic HCV infection (HCV RNA+) or youth (<25 years old) or CD4+ cell count nadir less than 200 cells/μl. Low: CD4+ cell count greater than 300 cells/μl with viral load less than 40 copies/ml
Undetectable = viral load under 40 copies/ml; viremia = viral load over 200 copies/ml.
Results from the Poisson regression model with robust variance estimation, overall and by risk category.
| Variableb | Estimatea (95% CI) | |
| All risk categories (implementation phase: | ||
| (Intercept) | 0.576 (0.500–0.664) | <0.001 |
| Imp | 1.179 (1.022–1.359) | 0.023 |
| Sex | 0.918 (0.783–1.076) | 0.290 |
| Age | 0.999 (0.993–1.005) | 0.795 |
| Canada | 0.799 (0.686–0.931) | 0.004 |
| High-risk category (Implementation phase: | ||
| (Intercept) | 0.665 (0.487–0.909) | 0.011 |
| Imp | 1.201 (0.879–1.640) | 0.250 |
| Sex | 0.835 (0.613–1.139) | 0.256 |
| Age | 1.005 (0.994–1.016) | 0.391 |
| Canada | 0.762 (0.533–1.090) | 0.137 |
| Intermediate-risk category (implementation phase: | ||
| (Intercept) | 0.601 (0.505–0.716) | <0.001 |
| Imp | 1.116 (0.938–1.329) | 0.216 |
| Sex | 0.905 (0.742–1.104) | 0.327 |
| Age | 0.999 (0.992–1.007) | 0.872 |
| Canada | 0.889 (0.740–1.067) | 0.207 |
| Low-risk category (implementation phase: | ||
| (Intercept) | 0.345 (0.222–0.536) | <0.001 |
| Imp | 1.658 (1.029–2.671) | 0.038 |
| Sex | 1.018 (0.606–1.710) | 0.947 |
| Age | 0.986 (0.965–1.007) | 0.184 |
| Canada | 0.536 (0.326–0.881) | 0.014 |
CI, confidence interval.
Risk for ’(Intercept)’, risk ratio otherwise.
‘Imp’ is a binary variable for being marked out of HIV care (OOC) in the implementation phase, compared with the pre-implementation phase.
‘Sex’ is a binary variable for the patient's sex, as documented in their electronic medical record, where females are assigned a value of 1.
‘Age’ is the patients age, centered at age 50 years.
‘Canada’ is a binary variable where patients born in Canada are assigned a value of 1.